Adult Cohort: <br/ >1. Acute illness including COVID-19 with or without fever at the time of study vaccine administration <br/ >2. History of laboratory confirmed (by PCR or serology to SARSCoV-2) COVID-19 disease. <br/ >3. History of severe allergic reactions after previous vaccinations or hypersensitivity to any component of study vaccines <br/ >4. Prior receipt of an investigational or licensed vaccine likely to <br/ >impact interpretation of the trial data <br/ >5. Current or planned participation in prophylactic drug trials for the <br/ >duration of the study <br/ >Pediatric Cohort <br/ >1. Acute illness including COVID-19 with or without fever at the time of study vaccine administration <br/ >2. History of laboratory confirmed (by PCR or serology to SARS-CoV-2) COVID-19 disease <br/ >3. History of severe allergic reactions after previous vaccinations or hypersensitivity to any component of study vaccines

Adult Cohort: <br/ >1. Acute illness including COVID-19 with or without fever at the time of study vaccine administration <br/ >2. History of laboratory confirmed (by PCR or serology to SARSCoV-2) COVID-19 disease. <br/ >3. History of severe allergic reactions after previous vaccinations or hypersensitivity to any component of study vaccines <br/ >4. Prior receipt of an investigational or licensed vaccine likely to <br/ >impact interpretation of the trial data <br/ >5. Current or planned participation in prophylactic drug trials for the <br/ >duration of the study <br/ >Pediatric Cohort <br/ >1. Acute illness including COVID-19 with or without fever at the time of study vaccine administration <br/ >2. History of laboratory confirmed (by PCR or serology to SARS-CoV-2) COVID-19 disease <br/ >3. History of severe allergic reactions after previous vaccinations or hypersensitivity to any component of study vaccines

N/A

N/A

1. Acute illness including COVID-19 with or without fever at the time of study vaccine administration <br/ >2. History of laboratory confirmed (by PCR or serology to SARSCoV-2) COVID-19 disease. <br/ >3. History of severe allergic reactions after previous vaccinations or hypersensitivity to any component of study vaccines <br/ >4. Prior receipt of an investigational or licensed vaccine likely to <br/ >impact interpretation of the trial data <br/ >5. Current or planned participation in prophylactic drug trials for the <br/ >duration of the study <br/ >6. Prior receipt of an investigational or licensed vaccine likely to impact interpretation of the trial data <br/ >7. Prior receipt of a COVID-19 vaccine or planning to receive a COVID-19 vaccine during the course of the study. <br/ >8. Pregnant or breast-feeding <br/ >9. Individuals who are part of study team or close family members of individuals conducting this study

1. Acute illness including COVID-19 with or without fever at the time of study vaccine administration <br/ >2. History of laboratory confirmed (by PCR or serology to SARSCoV-2) COVID-19 disease. <br/ >3. History of severe allergic reactions after previous vaccinations or hypersensitivity to any component of study vaccines <br/ >4. Prior receipt of an investigational or licensed vaccine likely to <br/ >impact interpretation of the trial data <br/ >5. Current or planned participation in prophylactic drug trials for the <br/ >duration of the study <br/ >6. Prior receipt of an investigational or licensed vaccine likely to impact interpretation of the trial data <br/ >7. Prior receipt of a COVID-19 vaccine or planning to receive a COVID-19 vaccine during the course of the study. <br/ >8. Pregnant or breast-feeding <br/ >9. Individuals who are part of study team or close family members of individuals conducting this study